Search

In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023 Additi

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Mas

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV.

New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR’s Axiomer technology

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) --

Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025 Axiomer activity demonstrated across multiple preclinical in vitro

Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favora